Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

243.86USD
28 Apr 2017
Change (% chg)

-- (--)
Prev Close
$243.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,210,063
52-wk High
$261.27
52-wk Low
$184.50

Latest Key Developments (Source: Significant Developments)

Allergan agrees to acquire Zeltiq for $2.48 bln
Monday, 13 Feb 2017 08:00am EST 

Allergan Plc : Allergan has agreed to acquire Zeltiq for $56.50 per share, or $2.475 billion . Deal for for $56.50 per share . Allergan to acquire Zeltiq, best-in-class company in fast-growing body contouring segment, for $2.47 billion . Acquisition of Zeltiq is immediately accretive .Moelis & Company is acting as financial advisor to Allergan, and Debevoise & Plimpton LLP is acting as lead legal counsel.  Full Article

Allergan says does not see U.S. tax reform in 2017
Wednesday, 8 Feb 2017 09:49am EST 

Allergan Plc - : Allergan CEO "We have a good report card for 2016 and a positive outlook for 2017 and beyond" . Allergan CEO "We are optimistic that the new administration is pro-growth, pro-innovation and against overregulation that could stifle investment & growth" . Allergan CEO says is pleased to see number of peers are following the Co's lead & becoming vocal about actions they are taking to price products responsibly . Allergan chief commercial officer says is pleased with performance of viberzi; says "it looks and feels just like linzess" . Allergan CEO says "We are engaged with the new administrationand certainly the key folks within congress" . Allergan CEO: "There's no real plan yet for what tax reform will look like nor when it will appear" . Allergan CEO: "something that could be detrimental or have a negative effect could be a border adjustment" . Allergan exec says "In August, we will evaluate whether to sell Teva stock" . Allergan exec says expected U.S. Tax reform does not change co's view on capital deployment, specifically for 2017 . Allergan CEO "i don't think we will see tax reform in 2017" . Allergan says could see some volume erosion for restatis with some modest price appreciation in 2017 or, the reverse, depending on formulary coverage . Allergan: in Q4 there were no surprises with restasis, no major swings in wholesaler buying patterns; growth was driven by a solid mix of volume & price.  Full Article

Allergan declares first quarterly cash dividend of $0.70 per ordinary share
Friday, 3 Feb 2017 08:04am EST 

Allergan Plc - :Allergan declares first quarterly cash dividend of $0.70 per ordinary share.  Full Article

U.S. FDA approves 72 mcg dose of linzess® (linaclotide) for adults with chronic idiopathic constipation
Thursday, 26 Jan 2017 07:01am EST 

Allergan Plc : Says new dose is expected to be available in q1 of 2017 .U.S. Food and Drug Administration approves 72 mcg dose of linzess® (linaclotide) for adults with chronic idiopathic constipation.  Full Article

Allergan announces FDA approval of RHOFADE cream
Thursday, 19 Jan 2017 07:59am EST 

Allergan Plc : Allergan announces FDA approval of RHOFADE™ (oxymetazoline hydrochloride) cream, 1% for the topical treatment of persistent facial Erythema associated with Rosacea in adults .Allergan Plc - RHOFADE will be available for commercial supply starting may 2017 in United States.  Full Article

Allergan enters parkinson's disease through option arrangement with Lysosomal Therapeutics
Monday, 9 Jan 2017 08:30am EST 

Allergan Plc : Allergan enters parkinson's disease through option arrangement with Lysosomal Therapeutics Inc (LTI) for its potential first-in-class breakthrough compounds . Allergan Plc - additional terms were not disclosed. . Allergan Plc - purchased an option right directly from LTI shareholders to acquire LTI following completion of a phase 1b trial for LTI-291 . Allergan Plc - option to acquire LTI following completion of phase 1B clinical trial . Allergan Plc - Allergan will provide a separate upfront research and development payment .Allergan Plc - Allergan and LTI will establish a joint development committee to oversee development activities for LTI-291.  Full Article

Allergan enters into licensing agreement with Assembly Biosciences
Monday, 9 Jan 2017 08:00am EST 

Allergan Plc : Will make upfront payment to assembly of $50 million for exclusive, worldwide rights to develop and commercialize UC, CD and IBS compounds . Assembly will be entitled to receive success-based development and commercial milestone payments . Assembly is also eligible to receive tiered royalties based on net sales . Co, Assembly will share development costs through proof-of-concept (POC) studies, and Allergan will assume all post-POC development costs .Allergan enters into licensing agreement with Assembly Biosciences to obtain worldwide rights to microbiome gastrointestinal development programs.  Full Article

Allergan CEO says will not take second price increase in June
Thursday, 5 Jan 2017 11:00am EST 

Allergan Plc - : Allergan CEO says proper guidance will come in a few weeks; but we've said Restasis net revenue will stay flat, "I think that's conservative" . Allergan CEO: "It seems the industry is taking pricing seriously...I'm encouraged by what I've seen in January so far" . Allergan CEO: "let's see what happens in June, we will not be taking a second increase in June" . Allergan CEO says we would like to see even stronger growth internationally, and think that's possible . Allergan CEO says in terms of data & submissions 2018 is a bigger year than 2017 . Allergan CEO: "its completely within the control of the industry", when asked about incoming Trump administration and its plans . Allergan CEO: "we're not asking people not to take price increases, but to be thoughtful of their price increases" Further company coverage: [AGN.N] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Allergan says about 40.5 mln shares worth $8 bln were received, retired during Nov. 2016
Friday, 2 Dec 2016 07:44am EST 

Allergan Plc : Allergan provides update on accelerated share repurchase (ASR) program . Allergan Plc - approximately 40.5 million shares worth $8 billion were received and retired by Allergan during November 2016 .Allergan Plc - remaining shares, if any, under ASR will be received and retired by Q3 of 2017.  Full Article

Allergan completes acquisition of Chase Pharmaceuticals
Tuesday, 22 Nov 2016 04:15pm EST 

Allergan Plc : Allergan acquires Chase Pharmaceuticals to expand CNS research and development pipeline and build on commitment to alzheimer's disease . Deal for an upfront payment of $125 million . Allergan to advance CPC-201 into Phase 3 registration study in 2017 . Deal includes additional potential milestone payments related to chase's lead compound, CPC-201, and certain backup compounds .Allergan plc - Allergan to advance cpc-201 into phase 3 registration study in 2017.  Full Article

More From Around the Web

BRIEF-Allergan completes Zeltiq acquisition

* Allergan successfully completes zeltiq® aesthetics acquisition Source text for Eikon: Further company coverage: